Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

Phase 4

Completed

• Conditions: Basal Cell Carcinoma
• Interventions: Biological: Imiquimod and Interferon alpha

• Registration Number: NCT00581425
• Lead Sponsor: The University of Texas Health Science Center, Houston

Brief Summary

A trial to see if BCC excluding the scalp and face can be treated successfully with a combination therapy of Intron-A and Aldara.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-12
• Study First Submitted: 2007-12-21
• Study First Submitted QC: 2007-12-26
• Study First Posted: 2007-12-27
• Primary Completion: 2011-09
• Study Completion: 2011-09
• Status Verified: 2013-01
• Last Update Submitted: 2013-01-23
• Last Update Posted: 2013-01-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

• Nodular or superficial basal cell carcinoma on the skin excluding scalp or face

Exclusion Criteria

• Pregnancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treated	Imiquimod and Interferon alpha	-

Primary Outcome Measures

Name	Time	Method
resolution of basal cell carcinoma	2 years

Secondary Outcome Measures

Name	Time	Method
resolution of basal cell carcinoma at a lower cost and less inflammation.	2 years

Trial Locations

Locations (1)

University of Texas Health Science Center of Houston Dermatology Clinic; 🇺🇸 Houston, Texas, United States